Westside Investment Management Inc. Grows Stock Position in SPDR S&P Biotech ETF (NYSEARCA:XBI)

Westside Investment Management Inc. increased its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 3.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 6,170 shares of the exchange traded fund’s stock after acquiring an additional 200 shares during the period. Westside Investment Management Inc.’s holdings in SPDR S&P Biotech ETF were worth $610,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Hartline Investment Corp increased its position in shares of SPDR S&P Biotech ETF by 2.0% during the 3rd quarter. Hartline Investment Corp now owns 5,502 shares of the exchange traded fund’s stock worth $544,000 after purchasing an additional 106 shares during the last quarter. Intellectus Partners LLC boosted its stake in SPDR S&P Biotech ETF by 1.0% during the second quarter. Intellectus Partners LLC now owns 11,334 shares of the exchange traded fund’s stock worth $1,051,000 after buying an additional 113 shares during the period. Signature Estate & Investment Advisors LLC increased its position in shares of SPDR S&P Biotech ETF by 5.7% during the third quarter. Signature Estate & Investment Advisors LLC now owns 2,336 shares of the exchange traded fund’s stock valued at $231,000 after acquiring an additional 125 shares during the last quarter. Denver Wealth Management Inc. lifted its holdings in shares of SPDR S&P Biotech ETF by 0.9% in the 3rd quarter. Denver Wealth Management Inc. now owns 14,779 shares of the exchange traded fund’s stock worth $1,460,000 after acquiring an additional 127 shares during the last quarter. Finally, Resources Management Corp CT ADV lifted its holdings in shares of SPDR S&P Biotech ETF by 30.3% in the 2nd quarter. Resources Management Corp CT ADV now owns 593 shares of the exchange traded fund’s stock worth $55,000 after acquiring an additional 138 shares during the last quarter.

SPDR S&P Biotech ETF Stock Performance

SPDR S&P Biotech ETF stock opened at $96.97 on Thursday. The company has a market capitalization of $7.39 billion, a PE ratio of 11.47 and a beta of 1.11. SPDR S&P Biotech ETF has a fifty-two week low of $77.78 and a fifty-two week high of $105.47. The firm has a 50 day moving average price of $98.18 and a 200 day moving average price of $96.99.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.